Company / Shareholders' Equity
Viking Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$639.1M
FY2025
5-year range
$145.3M / $880.3M
FY2021-FY2025
Trend
-27.4%
vs FY2024
Sector context
#72 of 213
Health Care
What the data says
At $639M, Viking Therapeutics, Inc.'s shareholders' equity ranks #72 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $8M in FY2016 to $880M in FY2024.
Based on SEC 10-K filings.
$639M in FY2025 with a 5-year CAGR of +21.2%.
Improved from $348M to $639M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +63.8%
- 5-Year CAGR
- +21.2%
- 10-Year CAGR
- -
Sector benchmark
#72 of 213 in Health CareTop 34% of 213This company $639.1M Sector average $2.5B
▼
-74.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.2%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 27.4% year-over-year.
- Ranks #72 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $639.1M | -27.4% |
| FY2024 | $880.3M | +152.6% |
| FY2023 | $348.4M | +139.8% |
| FY2022 | $145.3M | -28.0% |
| FY2021 | $201.9M | -17.4% |
| FY2020 | $244.3M | -11.8% |
| FY2019 | $277.1M | -6.9% |
| FY2018 | $297.8M | +2111.5% |
| FY2017 | $13.5M | +67.4% |
| FY2016 | $8.0M | -7.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026